Leuprorelin depot injection: patient considerations in the management of prostatic cancer
about
Sustained-release delivery of octreotide from biodegradable polymeric microspheres.Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
P2860
Leuprorelin depot injection: patient considerations in the management of prostatic cancer
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Leuprorelin depot injection: patient considerations in the management of prostatic cancer
@en
type
label
Leuprorelin depot injection: patient considerations in the management of prostatic cancer
@en
prefLabel
Leuprorelin depot injection: patient considerations in the management of prostatic cancer
@en
P2860
P356
P1476
Leuprorelin depot injection: patient considerations in the management of prostatic cancer
@en
P2093
E David Crawford
Zinelabidine Abouelfadel
P2860
P304
P356
10.2147/TCRM.S6863
P577
2008-04-01T00:00:00Z